Fig. 1
From: Ceritinib is a novel triple negative breast cancer therapeutic agent
ACK1 is a major Ceritinib target in MDA-MB 453. (A) The levels of phosphorylated tyrosine kinases in a panel of 73 RTKs were analyzed by a human RTK Phosphorylation Antibody Array C1 Kit (RayBiotech) after MDA-MB 453 cells were treated with 10 μM ceritinib, DMSO was used as control. The positive dot#1,#2,#3 are all controlled amount of biotinylated antibody, which is consistent from array to array. As such, the intensity of these Positive Control signals serves much like housekeeping proteins. (B) The densitometric values of phospho-RTKs were determined by an image lab software (Bio-Rad). The relative intensities of the duplicated spots were normalized to positive control 1 spots. Values represent the mean of duplicate spots for each protein after normalization. (C) AR and ACK1 were determined by WB assay in human breast cancer cell lines and (D) in human breast cancer tissues